Related Experiment Video

Updated: Apr 22, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.3K

CAMK2N1 inhibits prostate cancer progression through androgen receptor-dependent signaling

Tao Wang1, Shuiming Guo1, Zhuo Liu1

  • 1Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

Oncotarget
|October 10, 2014
PubMed

Insights

Calcium/calmodulin-dependent protein kinase II inhibitor 1 (CAMK2N1) acts as a tumor suppressor in prostate cancer. Reduced CAMK2N1 levels correlate with endocrine therapy resistance, suggesting it determines treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Endocrinology

Background:

  • Castration resistance poses a significant challenge in prostate cancer hormonal therapy.
  • Androgen independence contributes to endocrine resistance, but androgen receptor deregulation mechanisms remain unclear.

Purpose of the Study:

  • To investigate the role of CAMK2N1 in prostate cancer growth and survival.
  • To elucidate the mechanism of CAMK2N1 in androgen receptor (AR) signaling and endocrine resistance.

Main Methods:

  • Assessed CAMK2N1 contribution to prostate cancer cell growth and survival via AR-dependent signaling.
  • Correlated CAMK2N1 expression with recurrence-free survival in prostate cancer patients.
  • Investigated the auto-regulatory feedback loop between CAMK2N1 and AR signaling using CAMKII and AKT pathways.
  • Examined the effect of CAMK2N1 knockdown and re-expression on Casodex sensitivity in prostate cancer cells.

Main Results:

  • CAMK2N1 promotes human prostate cancer cell growth and survival through AR-dependent signaling.
  • Reduced CAMK2N1 expression correlates with shorter recurrence-free survival in patients with high AR levels.
  • CAMK2N1 and AR signaling form a negative feedback loop: AR activation down-regulates CAMK2N1, while CAMK2N1 inhibits AR expression and transactivation.
  • CAMK2N1 knockdown alleviates Casodex resistance, whereas CAMK2N1 re-expression sensitizes castration-resistant cells to Casodex.

Conclusions:

  • CAMK2N1 exhibits tumor suppressive functions in prostate cancer.
  • CAMK2N1 is a critical determinant of prostate cancer endocrine therapy resistance.
  • Targeting CAMK2N1 may offer a strategy to overcome resistance to hormonal therapies.

More Related Videos

Murine Prostate Micro-dissection and Surgical Castration08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

46.7K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

5.8K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.3K
Calmodulin-dependent Signaling01:16

Calmodulin-dependent Signaling

Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
4.8K